Raiffeisen Bank International AG Has $1.37 Million Holdings in Royalty Pharma PLC $RPRX

Raiffeisen Bank International AG increased its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 116.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 38,982 shares of the biopharmaceutical company’s stock after acquiring an additional 20,982 shares during the quarter. Raiffeisen Bank International AG’s holdings in Royalty Pharma were worth $1,374,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Royal Bank of Canada grew its position in shares of Royalty Pharma by 367.7% during the 1st quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock worth $6,342,000 after purchasing an additional 160,191 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Royalty Pharma by 20.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock valued at $2,490,000 after buying an additional 13,489 shares during the period. Focus Partners Wealth bought a new stake in shares of Royalty Pharma in the first quarter valued at approximately $264,000. Intech Investment Management LLC grew its position in Royalty Pharma by 41.0% during the first quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock worth $1,494,000 after buying an additional 13,951 shares in the last quarter. Finally, D.A. Davidson & CO. increased its stake in Royalty Pharma by 4.3% during the 2nd quarter. D.A. Davidson & CO. now owns 39,247 shares of the biopharmaceutical company’s stock worth $1,414,000 after acquiring an additional 1,612 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, EVP George W. Lloyd sold 110,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $39.77, for a total value of $4,374,700.00. Following the sale, the executive vice president owned 110,000 shares in the company, valued at $4,374,700. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Terrance P. Coyne sold 114,954 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $42.84, for a total transaction of $4,924,629.36. Following the sale, the chief financial officer directly owned 23,972 shares in the company, valued at approximately $1,026,960.48. The trade was a 82.74% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 1,034,602 shares of company stock valued at $41,353,043. 18.90% of the stock is owned by insiders.

Royalty Pharma Price Performance

Shares of RPRX stock opened at $45.12 on Friday. The business has a fifty day simple moving average of $41.08 and a 200 day simple moving average of $38.55. The company has a market cap of $26.05 billion, a P/E ratio of 33.42 and a beta of 0.42. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88. Royalty Pharma PLC has a twelve month low of $29.66 and a twelve month high of $46.14.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.13. The firm had revenue of $621.99 million for the quarter, compared to analysts’ expectations of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. On average, sell-side analysts forecast that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 20th will be given a dividend of $0.235 per share. The ex-dividend date is Friday, February 20th. This represents a $0.94 dividend on an annualized basis and a yield of 2.1%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio is currently 65.19%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. UBS Group upgraded Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 target price for the company in a research report on Friday, January 30th. Leerink Partners set a $45.00 price target on Royalty Pharma in a research note on Thursday, December 11th. Weiss Ratings raised shares of Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, February 12th. Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Finally, Morgan Stanley restated an “overweight” rating and issued a $61.00 target price on shares of Royalty Pharma in a research report on Thursday, February 12th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Royalty Pharma has an average rating of “Buy” and a consensus price target of $48.67.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.